Hill-Rom Holdings Inc. (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Post a promising third quarter by Hill-Rom, we are upbeat about the company to remain on a solid growth trajectory over the near term. The company’s year-over-year outcome was impressive along with record level of gross margin. Based on several positive catalysts, we expect the company to expand geographically in the coming quarters. Notably, in the last reported quarter, Hill-Rom posted strong growth in both Asia-Pacific and the U.S. While we remain impressed with the company’s increased bottom-line guidance for fiscal 2016, the revenue guidance was quite discouraging. Moreover, Hill-Rom’s persistent poor performance in the International front, especially in the Middle East and Latin America keeps us concerned. Unfortunately no near term improvement can be expected in the existing capital crunch condition that eventually led to economic and political downturns in these economies.”

Other analysts also recently issued reports about the company. KeyCorp restated a “buy” rating and set a $59.00 price objective on shares of Hill-Rom Holdings in a research report on Thursday, June 23rd. Morgan Stanley upgraded Hill-Rom Holdings from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $54.00 to $62.00 in a research report on Thursday, June 16th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Hill-Rom Holdings has a consensus rating of “Buy” and an average target price of $61.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/hill-rom-holdings-inc-hrc-rating-lowered-to-hold-at-zacks-investment-research-2.html

Hill-Rom Holdings (NYSE:HRC) traded down 0.471% during trading on Tuesday, hitting $59.409. The stock had a trading volume of 168,623 shares. Hill-Rom Holdings has a 52 week low of $42.99 and a 52 week high of $60.48. The company has a 50-day moving average of $58.05 and a 200 day moving average of $52.13. The company has a market cap of $3.89 billion, a price-to-earnings ratio of 61.183 and a beta of 1.06.

Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.05. Hill-Rom Holdings had a return on equity of 16.62% and a net margin of 2.47%. The business earned $655.40 million during the quarter, compared to the consensus estimate of $647.75 million. During the same period in the prior year, the company earned $0.62 EPS. Hill-Rom Holdings’s revenue for the quarter was up 38.1% on a year-over-year basis. On average, equities research analysts anticipate that Hill-Rom Holdings will post $3.33 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 16th will be given a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $0.68 annualized dividend and a yield of 1.14%. Hill-Rom Holdings’s dividend payout ratio is presently 73.91%.

A number of institutional investors have recently bought and sold shares of HRC. Acrospire Investment Management LLC bought a new stake in shares of Hill-Rom Holdings during the first quarter valued at $111,000. BlueMountain Capital Management LLC boosted its stake in shares of Hill-Rom Holdings by 36.5% in the second quarter. BlueMountain Capital Management LLC now owns 2,343 shares of the medical technology company’s stock valued at $118,000 after buying an additional 626 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Hill-Rom Holdings by 30.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,454 shares of the medical technology company’s stock valued at $123,000 after buying an additional 568 shares during the last quarter. LS Investment Advisors LLC boosted its stake in shares of Hill-Rom Holdings by 67.4% in the second quarter. LS Investment Advisors LLC now owns 3,783 shares of the medical technology company’s stock valued at $191,000 after buying an additional 1,523 shares during the last quarter. Finally, Bluestein R H & Co. bought a new stake in shares of Hill-Rom Holdings during the second quarter valued at $202,000. Hedge funds and other institutional investors own 83.11% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

5 Day Chart for NYSE:HRC

Get a free copy of the Zacks research report on Hill-Rom Holdings (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.